Madrigal Pharmaceuticals (MDGL) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) recently:

• 11/5/2024 – Madrigal Pharmaceuticals had its price target raised by analysts at B. Riley from $194.00 to $236.00. They now have a “neutral” rating on the stock.
• 11/1/2024 – Madrigal Pharmaceuticals had its price target raised by analysts at UBS Group AG from $411.00 to $441.00. They now have a “buy” rating on the stock.
• 10/23/2024 – Madrigal Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $375.00 to $350.00. They now have an “outperform” rating on the stock.
• 10/22/2024 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $390.00 price target on the stock.
• 10/12/2024 – Madrigal Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
• 10/11/2024 – Madrigal Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald.
• 10/2/2024 – Madrigal Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
• 9/20/2024 – Madrigal Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.

Madrigal Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ MDGL opened at $350.70 on Monday. The business has a fifty day moving average of $236.51 and a two-hundred day moving average of $247.32. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. Madrigal Pharmaceuticals, Inc. has a 52-week low of $133.99 and a 52-week high of $368.29. The stock has a market cap of $7.65 billion, a PE ratio of -13.98 and a beta of -0.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.94) by $2.02. The company had revenue of $62.18 million for the quarter, compared to analyst estimates of $34.60 million. During the same quarter in the previous year, the firm posted ($5.34) earnings per share. As a group, equities research analysts expect that Madrigal Pharmaceuticals, Inc. will post -24.08 earnings per share for the current fiscal year.

Insider Transactions at Madrigal Pharmaceuticals

In related news, Director Richard S. Levy sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the transaction, the director now directly owns 11,012 shares of the company’s stock, valued at approximately $3,313,951.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Richard S. Levy sold 5,000 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the completion of the sale, the director now directly owns 11,012 shares in the company, valued at $3,313,951.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO William John Sibold sold 6,363 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $243.83, for a total value of $1,551,490.29. Following the sale, the chief executive officer now owns 55,887 shares of the company’s stock, valued at approximately $13,626,927.21. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 22.80% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MDGL. Intech Investment Management LLC bought a new stake in shares of Madrigal Pharmaceuticals in the third quarter valued at $1,280,000. Quest Partners LLC grew its position in shares of Madrigal Pharmaceuticals by 172.8% in the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 368 shares in the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Madrigal Pharmaceuticals by 2.1% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,507 shares of the biopharmaceutical company’s stock valued at $320,000 after purchasing an additional 31 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Madrigal Pharmaceuticals by 1.8% in the third quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 40 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Madrigal Pharmaceuticals by 8.3% in the third quarter. Assetmark Inc. now owns 3,942 shares of the biopharmaceutical company’s stock valued at $837,000 after purchasing an additional 303 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.